[Synchronized cardioversion]] is recommended for acute treatment in<unk><unk>  and<unk>  who are hemodynamically unstable. Acute antithrombotic therapy is recommended in<unk><unk>  who have AT or atrial flutter to align with recommended antithrombotic therapy for<unk>  with AF. Intravenous diltiazem or esmolol (with extra caution used for either agent, observing for the development of hypotension) is recommended for acute treatment in<unk><unk>  and<unk>  who are hemodynamically stable. Intravenous adenosine is recommended for acute treatment in<unk><unk>  and<unk> . Ongoing<unk>  with antithrombotic therapy is recommended in<unk><unk>  and AT or atrial flutter to align with recommended antithrombotic therapy for<unk>  with AF. Assessment of associated hemodynamic abnormalities for potential repair of structural defects is recommended in<unk><unk>  as part of therapy for<unk> .  Flecainide should not be administered for treatment of<unk>  in<unk><unk>  and significant ventricular dysfunction.
Supraventricular tachycardia AHA recommendations for Management of SVT in ACHD Patients
Supraventricular tachycardia AHA recommendations for Management of IST
Supraventricular tachycardia AHA recommendations for Management of Atrial Flutter
Supraventricular tachycardia AHA recommendations for Management of AVNRT
Supraventricular tachycardia AHA recommendations for Management of Junctional Tachycardia
Supraventricular tachycardia AHA recommendations for Management of Orthodromic AVRT
Supraventricular tachycardia AHA recommendations for Management of Multifocal Atria Tachycardia
Supraventricular tachycardia AHA recommendations for Management of Suspected Focal Atrial Tachycardia